News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Practical Perspectives in the Treatment of Small-Cell Lung Cancer

EP. 1: IMpower133 and CASPIAN Trials for Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

EP. 2: KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

EP. 3: Expert Approaches to Treating Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

EP. 4: Role of PCI Versus Brain MRI Surveillance in ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

EP. 5: Second- and Third-Line Treatment for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

EP. 6: Review of Treatment for Limited-Stage Small-Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL